Het Siemens INNOVANCE* PFA P2Y Test Cartridge Project

Patients must have a history of vascular disease (cardiovascular or cerebrovascular) or at least two of eight risk factors for developing vascular disease based on the following American Heart Association criteria:
• current or previous history of smoking
• hypertension
• hyperlipidemia
• family history of vascular disease
• post-menopausal females
• diabetes mellitus
• morbid obesity
• sedentary lifestyle
Other inclusion criteria
• >=18 years of age (18 to 90)
• Documented history of vascular disease (cardiovascular or cerebrovascular) or at least two of the risk factors for developing vascular disease described in §3.1
• Eligible to receive clopidogrel
• Indication for clopidogrel
• Able to provide written, informed consent in accordance with the IRB (internal review board or ethics committee) and agree to comply with all protocol-specified procedures

• <18 years of age
• Treatment with any drug inhibiting platelet function, such as GPIIb/IIIa inhibitors, ticlopidine or dipyridamole, but not acetylsalicylic acid (Aspirin®) or clopidogrel
• Known inherited or acquired platelet function disorder
• Known inherited or acquired von Willebrand disease
• Pathological CT with PFA ADP Cartridge (3.2% citrate) before intake of clopidogrel
• Current participation in another trial with a substance known to affect platelet function or any investigational new drug
• Platelet count < 150 x109/L to avoid interferences for LTA